Posted by Michael Wonder on 23 Feb 2025
Luxa Biotechnology announces FDA regenerative medicine advanced therapy designation granted to RPESC-RPE-4W transplantation for the treatment of dry age-related macular degeneration
19 February 2025 - Luxa Biotechnology today announced that the US FDA has granted regenerative medicine advanced therapy designation to RPESC-RPE-4W transplantation for the treatment of patients with dry age-related macular degeneration.
RPESC-RPE-4W is a cell product derived from adult retinal pigment epithelial stem cells that generate retinal pigmented epithelium cell progeny.
